Chinese laboratory Sinopharm announced on Wednesday that one of its Covid-19 vaccines was 79% effective, a figure lower than those claimed by its American competitors Pfizer and Moderna.
Sinopharm is the first Chinese pharmacist to report figures on the effectiveness of a vaccine in preparation. The Chinese authorities have nonetheless started to vaccinate more than a million people using products that they have not yet formally validated.
Lower efficiency rate than competitors
In a statement, Sinopharm reported an efficacy rate of 79.43% for this product developed by the CNBG laboratory in Beijing. This figure is lower than those for vaccines from Pfizer / BioNTech (95%) and Moderna (94.1%).
The British Astrazeneca, associated with the University of Oxford, for its part claimed an effectiveness rate of 70%, but which could reach 100% with two doses.
A “global public good”
China, where the new coronavirus appeared a year ago, has put enormous resources into the development of vaccines, which it has promised to make “a global public good”. The country, which has practically stopped the epidemic on its soil, has had to conduct clinical tests in foreign countries where the circulation of the virus remains intense.
Five Chinese vaccines are therefore in phase 3 clinical trials. Sinopharm has not specifically specified whether these trials have been completed for this first vaccine. The group said it had filed an application for approval of this first vaccine with the Chinese authorities.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
